A functional inflammasome activation assaydifferentiates patients with pathogenic NLRP3mutations and symptomatic patients with lowpenetrance variants. Issue 1 (December 2015) - Rieber, N; Gavrilov, A; Hofer, L; Singh, A; Öz, H; Endres, T; Schäfer, I; Handgretinger, R; Hartl, D; Kümmerle-Deschner, J